Tags

Type your tag names separated by a space and hit enter

Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients.
Metabolism. 1985 Oct; 34(10):917-22.M

Abstract

Recently, it has been shown that patients with a PRL-secreting pituitary adenoma have a greater thyroid stimulating hormone (TSH) release after dopamine (DA)-receptor blockade than normal subjects. We have compared the TSH and PRL responses to metoclopramide (MCP) in normal and postpartum lactating women with those in 28 patients with hyperprolactinemia of different origin. Patients with a PRL-secreting pituitary adenoma were also tested after transsphenoidal removal of the tumor in order to establish the prognostic value of this test in such patients. Following MCP administration, percent increases in plasma PRL levels were greater in normal female subjects than postpartum lactating women. Plasma TSH levels did not increase in postpartum women and had a modest increment in normal subjects. In patients with hypothalamic tumors and empty sella syndrome plasma PRL and TSH levels showed modest or no increases after MCP administration. In ten patients harboring a microprolactinoma, plasma TSH levels showed an exaggerated increment after DA-receptor blockade. Postoperatively, despite normal or borderline PRL levels in the immediate postoperative period, a TSH response to MCP was present (in five patients one to two weeks after the operation, and in five patients one to three years after the operation), suggesting an increased DA activity even in the absence of hyperprolactinemia. In conclusion, the TSH test can easily detect increased DA-activity in patients with a microprolactinoma both preoperatively and postoperatively. It is possible that some patients with increased DA-activity in presence of normal PRL levels and normal PRL responsiveness to stimulation will experience a recurrence of hyperprolactinemia.(

ABSTRACT

TRUNCATED AT 250 WORDS)

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

4046835

Citation

De Marinis, L, et al. "Evaluation of Dopaminergic Tone in Hyperprolactinemia. III. Thyroid-stimulating Hormone Response to Metoclopramide in Differential Diagnosis and Postoperative Follow-up of Prolactinoma Patients." Metabolism: Clinical and Experimental, vol. 34, no. 10, 1985, pp. 917-22.
De Marinis L, Mancini A, Minnielli S, et al. Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients. Metabolism. 1985;34(10):917-22.
De Marinis, L., Mancini, A., Minnielli, S., Masala, R., Anile, C., Maira, G., & Barbarino, A. (1985). Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients. Metabolism: Clinical and Experimental, 34(10), 917-22.
De Marinis L, et al. Evaluation of Dopaminergic Tone in Hyperprolactinemia. III. Thyroid-stimulating Hormone Response to Metoclopramide in Differential Diagnosis and Postoperative Follow-up of Prolactinoma Patients. Metabolism. 1985;34(10):917-22. PubMed PMID: 4046835.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Evaluation of dopaminergic tone in hyperprolactinemia. III. Thyroid-stimulating hormone response to metoclopramide in differential diagnosis and postoperative follow-up of prolactinoma patients. AU - De Marinis,L, AU - Mancini,A, AU - Minnielli,S, AU - Masala,R, AU - Anile,C, AU - Maira,G, AU - Barbarino,A, PY - 1985/10/1/pubmed PY - 1985/10/1/medline PY - 1985/10/1/entrez SP - 917 EP - 22 JF - Metabolism: clinical and experimental JO - Metabolism VL - 34 IS - 10 N2 - Recently, it has been shown that patients with a PRL-secreting pituitary adenoma have a greater thyroid stimulating hormone (TSH) release after dopamine (DA)-receptor blockade than normal subjects. We have compared the TSH and PRL responses to metoclopramide (MCP) in normal and postpartum lactating women with those in 28 patients with hyperprolactinemia of different origin. Patients with a PRL-secreting pituitary adenoma were also tested after transsphenoidal removal of the tumor in order to establish the prognostic value of this test in such patients. Following MCP administration, percent increases in plasma PRL levels were greater in normal female subjects than postpartum lactating women. Plasma TSH levels did not increase in postpartum women and had a modest increment in normal subjects. In patients with hypothalamic tumors and empty sella syndrome plasma PRL and TSH levels showed modest or no increases after MCP administration. In ten patients harboring a microprolactinoma, plasma TSH levels showed an exaggerated increment after DA-receptor blockade. Postoperatively, despite normal or borderline PRL levels in the immediate postoperative period, a TSH response to MCP was present (in five patients one to two weeks after the operation, and in five patients one to three years after the operation), suggesting an increased DA activity even in the absence of hyperprolactinemia. In conclusion, the TSH test can easily detect increased DA-activity in patients with a microprolactinoma both preoperatively and postoperatively. It is possible that some patients with increased DA-activity in presence of normal PRL levels and normal PRL responsiveness to stimulation will experience a recurrence of hyperprolactinemia.(ABSTRACT TRUNCATED AT 250 WORDS) SN - 0026-0495 UR - https://www.unboundmedicine.com/medline/citation/4046835/Evaluation_of_dopaminergic_tone_in_hyperprolactinemia__III__Thyroid_stimulating_hormone_response_to_metoclopramide_in_differential_diagnosis_and_postoperative_follow_up_of_prolactinoma_patients_ L2 - https://linkinghub.elsevier.com/retrieve/pii/0026-0495(85)90138-6 DB - PRIME DP - Unbound Medicine ER -